ロード中...
Alemtuzumab for Multiple Sclerosis
Alemtuzumab is a humanised anti-CD52 monoclonal antibody approved for use in active, relapsing multiple sclerosis (MS). Administration results in a rapid depletion of circulating lymphocytes with a subsequent beneficial immune reconstitution. Early open-label experience and recent clinical trials ha...
保存先:
| 出版年: | Curr Neurol Neurosci Rep |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4971037/ https://ncbi.nlm.nih.gov/pubmed/27485945 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11910-016-0685-y |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|